Radius Health | Gurnet Point Capital

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health*.

Investment Date

2022

Fund

Fund II

Status

Current

Website

https://radiuspharm.com

Related News

Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS®

Read

January 30, 2023

Radius Licensee Receives FDA Approval for ORSERDU™ (elacestrant)

Read

January 30, 2023

Teijin Pharma to Launch Japan-market Sales of Abaloparatide Acetate for Osteoporosis

Read

December 20, 2022

TYMLOS® (abaloparatide) Receives U.S. FDA Approval for Increase Bone Density in Men with Osteoporosis

Read

Fund II investments referenced herein have been completed by GPC through a warehouse facility provided by B-Flexion and are expected to be transferred to Fund II following its first closing. References to Fund II's investment activity to date are references to investments made by the warehouse facility.